Approvals In Brief
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Aptivus clears FDA for HIV: Labeling for Boehringer Ingelheim's HIV agent Aptivus (tipranavir) advocates use of genotypic or phenotypic testing and/or treatment history to help guide therapy. The non-peptidic protease inhibitor received accelerated approval June 22 for use with Abbott's Norvir (ritonavir) for "treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors." Accelerated approval was based on response rate in two 24-week, open-label Phase III trials; to support full approval, BI will submit 48-week data from two ongoing Phase III studies by Sept. 30, 2006. Postmarketing studies will look at therapeutic drug monitoring and drug-drug interactions. Like other protease inhibitors, Aptivus has an extensive interaction profile: it is either contraindicated or "not recommended" for concomitant use with 19 drugs...
You may also be interested in...
NitroMed’s BiDil XR Will Use Elan Delivery Technology Under Recent Deal
NitroMed aims to have a regulatory and development plan for an extended-release formulation of its heart failure combo therapy BiDil (isosorbide dinitrate/hydralazine) by the middle of the year, the firm told Pharmaceutical Approvals Monthly
Exubera clarification
Pfizer's inhaled insulin product Exubera is not a new molecular entity, according to FDA. Prior to the agent's January approval, the sponsor had referred to Exubera as a "new chemical compound" in filings with the Securities & Exchange Commission. Exubera "is native sequence human insulin and therefore is not technically an NME," according to FDA's Office of Drug Evaluation II. "The insulins that are NMEs…have different amino acid sequences," FDA explains. The most recently approved NME insulin is Novo Nordisk's Levemir (insulin detemir), approved in June 2005 (1Pharmaceutical Approvals Monthly July 2005, p. 15); prior to that, Sanofi-Aventis' Apidra (insulin glulisine) was cleared as an NME in April 2004. Exubera is the first inhaled insulin to clear FDA...
QLT Eligard Sales Suspended For Two Months; Aczone Could Launch In 2007
U.S. sales of QLT/Sanofi-Aventis' Eligard will be suspended for two months due to a patent dispute with rival leuprolide implant Lupron marketer TAP, despite a court ruling that allows for sales to continue